CMC out to prove it is the EU's answer to consistent device regulation
This article was originally published in Clinica
Executive Summary
The pressure is on for Europe's newly established Central Management Committee. It is in a two-horse race to prove that it can provide an effective means of centralising aspects of device regulation which the European Commission needs to divest. Matthias Neumann, CMC chair, explained to Amanda Maxwell how the committee is demonstrating it is a better option than the controversial European Medicines Agency alternative